A Phase I/II Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors.

Trial Profile

A Phase I/II Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors.

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 23 May 2018

At a glance

  • Drugs Etoposide (Primary) ; Vorinostat (Primary)
  • Indications CNS cancer; Liver cancer; Neuroblastoma; Rhabdomyosarcoma; Solid tumours; Wilms' tumour
  • Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 23 Feb 2018 Planned End Date changed from 1 Feb 2018 to 1 Feb 2019.
    • 23 Feb 2018 Planned primary completion date changed from 1 Feb 2018 to 1 Feb 2019.
    • 01 Mar 2017 Planned End Date changed from 1 Feb 2017 to 1 Feb 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top